Sernova to Present at Global Partnership Family Office - HealthCare & Biotechnology TSX Showcase
LONDON, ON - May 17, 2021 -- Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the virtual Global Partnership Family Office - Healthcare & Biotechnology TSX Showcase on May 19th, 2021. The Showcase is hosted by London, UK based International Deal Gateway (IDG).
The event is by invitation only and includes a selected group of inspiring leaders from innovative public companies in the healthcare, biotechnology and life sciences sector. Five leading companies listed on the TSX or TSX Venture have been selected to present live, via video, to GPFO investors.
"Deal Gateway's exclusive virtual events give innovative leaders the opportunity to introduce their companies to a very hard to reach audience of family offices and access new pools of capital in London, Geneva, Zurich and other key markets," said Elizabeth Priestman, CEO of IDG.
"Sernova is delighted to have been selected by the TSX to present to this exclusive group of sophisticated investors," said Dr. Philip Toleikis, President and CEO of Sernova. "This presentation aligns with our goal to increase the percentage of longer-term oriented institutional investors amongst our shareholder base who understand the value of innovative technologies. We look forward to presenting to them and outlining the potential of Sernova's innovative regenerative medicine platform, including potentially providing a 'functional cure" for diabetes and other chronic diseases."
Following the event, a recording will be available at www.sernova.com.
Selected Company Achievements
- Integrated regenerative medicine therapeutic platform solution including an implantable device with local immune protection (Conformal Coating Technology) that could eliminate the need for immunosuppressive medications to protect cells from immune system attack.
- First and only regenerative medicine therapeutics platform company to demonstrate an implantable well-vascularized subcutaneous cell transplant device technology achieving persistent islet graft function and clinical benefit as presented in the most advanced study patients in its ongoing US Phase I/II diabetes clinical trial.
|Diskussion: Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr !|